Allogeneic haematopoietic stem cell transplantation in myelodysplastic syndromes

Abstract

Allogeneic haematopoietic stem cell transplantation is curative in up to 40% of myelodysplastic syndrome patients. Appropriate patient selection, modification of conditioning regimes and donor selection should be considered carefully. A preemptive approach for the management of patients at high risk of relapse should be employed following transplant, with the use of immune modulating therapies such as donor lymphocyte infusion and azacitidine.

Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents

“…The topic of HSCT in MDS is complex, with many patientspecific variables to consider, including which patients are suitable transplant candidates, the best timing of transplant in the disease course, the optimal conditioning regimen, and post-HSCT management [73,74]. Nevertheless, HSCT remains the only possible cure for patients with MDS and should be considered in all potentially transplant-eligible patients after failure of HMAs [13,75].…”

The Rome Transplant Network model compared to the Italian Bone Marrow Donor Registry activity for unrelated donor search process and transplant efficiency for hematologic malignancy

“…Allogeneic stem cell transplantation represents a potentially curative treatment for several hematologic disorders, but its application depends on the availability of a suitable donor. It is well known that approximately 30% of patients might find an HLA‐identical sibling donor; however, due to the small average of family size, in some countries, such as the United States, this percentage progressively decreased to 20% .…”